Moderna displays progress of Covid-19 vaccine trial



[ad_1]

Moderna, Inc. (RNAm) – Get the report said on Wednesday it had reached a milestone in testing its Covid-19 vaccine candidate.

The company said it had completed “case counting for the first interim analysis of the COVE Phase 3 mRNA-1273 study,” its COVID-19 vaccine candidate. The report means that there are enough patients with Covid-19 in the study to allow an analysis of the efficacy of the candidate vaccine.

Moderna said it has seen “a significant increase in the rate of case identification at sites over the past week. As a result, the company expects the first interim scan to include significantly more than 53 cases, the targeted trigger point for the scan. “



[ad_2]

Source link